Novartis AG (NVS) Balance Sheet

NYSE: NVSAssets, liabilities, debt and equity over 10 years.

NVS balance sheet, 2025

December 31, 2025 · U.S. dollars

$115.57B assets = $69.02B liabilities + $46.55B equity

What it owns$115.57BCash & ST investments: $11.59B (10.0%)$11.59BReceivables: $10.93B (9.5%)Receivables $10.93BInventory: $6.27B (5.4%)Other current: $1.67B (1.4%)PP&E: $12.35B (10.7%)PP&E $12.35BGoodwill & intangibles: $54.98B (47.6%)Goodwill & intangibles$54.98B · 48%LT investments: $1.09B (0.9%)Other non-current: $16.69B (14.4%)Other non-current$16.69B · 14%=How it is financed$115.57BCurrent liabilities: $27.28B (23.6%)Current liabilities$27.28B · 24%Long-term debt: $29.59B (25.6%)Long-term debt$29.59B · 26%Other LT liabilities: $12.15B (10.5%)$12.15BShareholders’ equity: $46.55B (40.3%)Shareholders’ equity$46.55B · 40%

Both columns are drawn to the same scale: what NVS owns equals what it owes plus shareholders’ equity. Hover a block for its value.

NVS financial health

Current ratio1.12
Adequate · current assets cover current liabilities 1.12×
Debt / equity0.80
Moderate leverage · $0.80 of debt for each $1 of equity
Equity / assets39.9%
Balanced · of assets funded by shareholders
Cash / debt31.3%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles47.6%
Acquisition-heavy · of total assets

Descriptive bands, not a rating. Fiscal 2025.

NVS balance sheet trends, 2016–2025

Novartis AG balance sheet trends
MetricTrendThenLatestChange
Total assets$130.12B2016$115.57B2025−1.3%/yr
Total liabilities$55.23B2016$69.02B2025+2.5%/yr
Shareholders’ equity$74.83B2016$46.13B2025−5.2%/yr
Cash & short-term investments$7.78B2016$11.59B2025+4.5%/yr
Total debt$23.80B2016$37.03B2025+5.0%/yr
Net cash (debt)−$16.02B2016−$25.44B2025−$9.4B
Working capital$2.72B2016$3.18B2025+$460.0M
Book value per share$31.182016$23.602025−3.0%/yr
Current ratio1.1220161.122025−0.01
Debt / equity0.3220160.802025+0.48
Shares outstanding2.40B20161.96B2025−2.3%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

NVS assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

NVS liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

NVS debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

NVS balance sheet

Novartis AG annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$11.59B$13.35B$13.96B$18.61B$28.11B$11.56B$11.45B$15.96B$9.48B$7.78B
Cash & equivalents$11.44B$11.46B$13.39B$7.52B$12.41B$9.66B$11.11B$13.27B$8.86B$7.01B
Short-term investments$155.0M$1.89B$569.0M$11.10B$15.71B$1.91B$334.0M$2.69B$625.0M$770.0M
Receivables$10.93B$8.21B$9.38B$9.89B$9.62B$9.07B$9.17B$9.68B$10.07B$10.20B
Inventory$6.27B$5.72B$5.91B$7.17B$6.67B$7.13B$5.98B$6.96B$6.87B$6.25B
Other current assets$1.67B$2.42B$1.23B$1.23B$1.32B$1.91B$2.90B$2.97B$1.79B$697.0M
Total current assets$30.46B$29.70B$30.48B$36.91B$45.72B$29.67B$29.50B$35.56B$28.21B$24.93B
Property, plant & equipment (net)$12.35B$10.87B$10.92B$12.20B$13.11B$13.94B$13.75B$15.70B$16.46B$15.64B
Goodwill & intangible assets$54.98B$51.67B$50.22B$60.95B$63.78B$66.81B$55.31B$74.01B$61.75B$62.32B
Long-term investments$1.09B$1.13B$1.83B$1.61B$2.27B$11.70B$11.16B$10.70B$17.61B$16.50B
Other non-current assets$16.69B$8.87B$6.49B$5.80B$6.93B$10.07B$8.69B$9.59B$9.05B$10.73B
Total assets$115.57B$102.25B$99.94B$117.45B$131.79B$132.19B$118.41B$145.56B$133.08B$130.12B
Liabilities
Accounts payable$4.46B$4.57B$4.93B$5.15B$5.55B$5.40B$5.42B$5.56B$5.17B$4.87B
Short-term debt$5.78B$8.32B$6.31B$6.13B$6.50B$9.88B$7.09B$9.62B$5.20B$8.05B
Deferred revenue—$127.0M$98.0M$123.0M$123.0M$56.0M$114.0M$236.0M$305.0M$287.0M
Total current liabilities$27.28B$28.69B$26.39B$28.66B$30.21B$33.06B$28.26B$29.61B$23.40B$22.21B
Long-term debt$29.59B$22.93B$20.03B$21.78B$24.52B$27.98B$22.06B$22.47B$23.22B$17.90B
Lease obligations$1.92B$1.80B$1.83B$1.79B$1.90B$2.00B$1.95B———
Other long-term liabilities$12.15B$6.49B$6.77B$7.59B$9.24B$14.49B$12.54B$14.79B$12.22B$15.13B
Total liabilities$69.02B$58.12B$53.20B$58.03B$63.97B$75.52B$62.86B$66.87B$58.85B$55.23B
Shareholders' equity
Common stock & paid-in capital$766.0M$793.0M$825.0M$890.0M$901.0M$913.0M$936.0M$944.0M$969.0M$972.0M
Retained earnings (deficit)$44.72B$46.56B$49.65B$63.54B$70.99B$57.16B$59.27B$82.19B$77.64B$81.15B
Treasury stock——−$41.0M−$92.0M−$48.0M−$53.0M−$80.0M−$69.0M−$100.0M−$76.0M
Accumulated other comprehensive income$694.0M−$3.25B−$3.77B−$5.00B−$4.19B−$1.42B−$4.66B$77.74B$73.30B$73.94B
Minority interest$419.0M$80.0M$83.0M$81.0M$167.0M$68.0M$77.0M$78.0M$59.0M$59.0M
Total shareholders' equity$46.13B$44.05B$46.67B$59.34B$67.66B$56.60B$55.47B$78.61B$74.17B$74.83B
Key figures
Total debt$37.03B$31.26B$26.35B$27.91B$31.02B$37.85B$29.15B$32.09B$28.43B$23.80B
Net cash (debt)−$25.44B−$17.91B−$12.39B−$9.29B−$2.91B−$26.29B−$17.70B−$16.13B−$18.94B−$16.02B
Working capital$3.18B$1.01B$4.09B$8.25B$15.51B−$3.39B$1.24B$5.96B$4.80B$2.72B
Tangible book value−$8.85B−$7.62B−$3.55B−$1.60B$3.88B−$10.21B$163.0M$4.60B$12.42B$12.51B
Book value per share$23.60$21.64$22.31$27.01$29.94$24.65$23.92$33.54$31.28$31.18
Shares outstanding1.96B2.04B2.09B2.20B2.26B2.30B2.32B2.34B2.37B2.40B
Current ratio1.121.041.161.291.510.901.041.201.211.12
Quick ratio0.830.750.880.991.250.620.730.870.840.81
Debt / equity0.800.710.560.470.460.670.530.410.380.32
Equity / assets39.9%43.1%46.7%50.5%51.3%42.8%46.8%54.0%55.7%57.5%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 4, 2026); data from EODHD.

NVS financial position

At the end of fiscal 2025 (December 31, 2025), Novartis had total assets of $115.6 billion (up 13.0% from a year earlier), total liabilities of $69.0 billion and shareholders' equity of $46.1 billion. It held $11.6 billion in cash and short-term investments against $37.0 billion of debt, net debt of $25.4 billion. Its current ratio was 1.12. In the latest quarter (ended June 30, 2026) total assets were $122.0 billion and equity $41.5 billion.

Related: NVS income statement, NVS cash flow statement, NVS key metrics. See the NVS stock overview for the latest quote and news.

NVS balance sheet FAQ

What are Novartis's total assets?

Novartis reported total assets of $115.6 billion at the end of fiscal 2025 (December 31, 2025), compared with $102.2 billion a year earlier.

How much debt does Novartis have?

Novartis had $37.0 billion of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.80.

How much cash does Novartis have?

Novartis held $11.6 billion in cash and short-term investments at the end of fiscal 2025; with $37.0 billion of debt that is net debt of $25.4 billion.

What is Novartis's book value?

Novartis's shareholders' equity (book value) was $46.1 billion at the end of fiscal 2025, or $23.60 per share.

What is Novartis's current ratio?

Novartis had current assets of $30.5 billion and current liabilities of $27.3 billion, a current ratio of 1.12 (it can cover its short-term obligations).

How much goodwill does Novartis have?

Novartis carried $55.0 billion of goodwill and intangible assets, 47.6% of total assets, at the end of fiscal 2025.

Drug Manufacturers - General: balance sheet